Certara, Inc. (CERT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Certara finished FY2025 with organic software revenue growth of 7%, squarely within its 6%-8% guidance, and delivered a 32% adjusted EBITDA margin, slightly above its 30%-32% target. Management characterized the year-end as strong on revenue and EBITDA while noting increased R&D investment. The company acknowledged 'lumpiness' and softer demand through 2025; no specific Q1 2026 numeric outlook was provided during the discussion.

Analysis

Certara’s strategic emphasis on software and R&D should compound margin and retention optionality over a multi-quarter horizon as customers consolidate analytics and modeling onto single platforms. If platform-led wins convert even a modest portion of legacy consulting spend into recurring ARR, present valuation gaps versus service-heavy peers will compress — expect visible evidence in renewal logos and multi-year contract disclosures within 2-4 quarters.

Second-order winners include cloud infra providers and niche data vendors: higher compute-intensity workflows (simulation, federated learning) push incremental spend to AWS/MSFT/GOOGL and specialized oncology/genomics data partners, improving Certara’s gross margin profile without proportionate headcount growth. Conversely, traditional CROs and low-margin consulting arms face secular contraction in per-trial revenue as model-informed designs reduce protocol iterations and shorten timelines.

Immediate tail risks are cadence-driven: uneven deal timing or a single large renewal loss can move fundamentals sharply over weeks, while broader pharma R&D budget retrenchment would be a 6–18 month adverse scenario that erodes bookings and upsell levers. Key positive catalysts to monitor are public pharma endorsements of model-informed drug development, several enterprise renewals, and tuck-in M&A that meaningfully expands addressable data inputs.

Market consensus appears to underweight the structural shift from services to software in drug development and over-penalize near-term lumpiness. That opens asymmetric trade setups that capture a re-rating if upcoming contract disclosures and regulatory acceptance accelerate platform adoption over the next 3–12 months.

Key Decisions for Investors

• Long CERT equity sized 2–4% of NAV with a 12-month horizon. Target +40% upside if adoption/renewal cadence accelerates; cut to flat on a 15% drawdown. Rationale: convex exposure to recurring ARR conversion with limited near-term dilution risk.
• Buy a 9–15 month CERT call spread (buy nearer-term ATM call, sell OTM call ~30–40% above) to capture upside from 2–4 quarter renewal catalysts while capping premium outlay. Risk: full premium loss; Reward: ~3:1 if shares reclaim growth multiple.
• Pair trade: long CERT / short a large service-heavy CRO (e.g., IQVIA) equal-dollar for 6–12 months. Expect divergence as software-led efficiencies compress CRO revenue per trial; target 20–30% relative outperformance, stop if pair diverges >15% adverse.
• Event hedge: buy 3–6 month put protection (~10–15% OTM) if near-term earnings or large client announcements are due within 6 weeks. Cost justified if headlines reveal meaningful renewal loss or macro R&D cuts that would reset bookings expectations.